These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 34154497)

  • 1. Pravastatin is useful for prevention of recurrent severe placenta-mediated complications - a pilot study.
    Kupferminc MJ; Kliger C; Rimon E; Asher-Landsberg J; Skornick-Rapaport A; Gamzu R; Yogev Y
    J Matern Fetal Neonatal Med; 2022 Dec; 35(25):8055-8061. PubMed ID: 34154497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of aspirin, heparin, and other interventions in the prevention and treatment of fetal growth restriction.
    Groom KM; David AL
    Am J Obstet Gynecol; 2018 Feb; 218(2S):S829-S840. PubMed ID: 29229321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-molecular-weight heparin for prevention of preeclampsia and other placenta-mediated complications: a systematic review and meta-analysis.
    Cruz-Lemini M; Vázquez JC; Ullmo J; Llurba E
    Am J Obstet Gynecol; 2022 Feb; 226(2S):S1126-S1144.e17. PubMed ID: 34301348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple therapy with pravastatin, low molecular weight heparin and low dose aspirin improves placental haemodynamics and pregnancy outcomes in obstetric antiphospholipid syndrome in mice and women through a nitric oxide-dependent mechanism.
    Lefkou E; Varoudi K; Pombo J; Jurisic A; Jurisic Z; Contento G; Girardi G
    Biochem Pharmacol; 2020 Dec; 182():114217. PubMed ID: 32926874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pravastatin plus L-arginine prevents adverse pregnancy outcomes in women with uteroplacental vascular dysfunction.
    Jurisic A; Jurisic Z; Lefkou E; Girardi G
    Vascul Pharmacol; 2021 Apr; 137():106824. PubMed ID: 33249273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low molecular weight heparin versus no treatment in women with previous severe pregnancy complications and placental findings without thrombophilia.
    Kupferminc M; Rimon E; Many A; Maslovitz S; Lessing JB; Gamzu R
    Blood Coagul Fibrinolysis; 2011 Mar; 22(2):123-6. PubMed ID: 21192252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early Prophylactic Enoxaparin for the Prevention of Preeclampsia and Intrauterine Growth Restriction: A Randomized Trial.
    Llurba E; Bella M; Burgos J; Mazarico E; Gómez-Roig MD; De Diego R; Martínez-Astorquiza T; Alijotas-Reig J; Sánchez-Durán MÁ; Sánchez O; Carreras E; Cabero L
    Fetal Diagn Ther; 2020; 47(11):824-833. PubMed ID: 33472201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study.
    Saccone G; Berghella V; Maruotti GM; Ghi T; Rizzo G; Simonazzi G; Rizzo N; Facchinetti F; Dall'Asta A; Visentin S; Sarno L; Xodo S; Bernabini D; Monari F; Roman A; Eke AC; Hoxha A; Ruffatti A; Schuit E; Martinelli P;
    Am J Obstet Gynecol; 2017 May; 216(5):525.e1-525.e12. PubMed ID: 28153662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating maternal placental growth factor responses to low-molecular-weight heparin in pregnant patients at risk of placental dysfunction.
    McLaughlin K; Hobson SR; Chandran AR; Agrawal S; Windrim RC; Parks WT; Bowman AW; Sovio U; Smith GC; Kingdom JC
    Am J Obstet Gynecol; 2022 Feb; 226(2S):S1145-S1156.e1. PubMed ID: 34461078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding and Preventing Placenta-Mediated Pregnancy Complications.
    Skeith L; Blondon M; Ní Áinle F
    Hamostaseologie; 2020 Aug; 40(3):356-363. PubMed ID: 32726830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of antithrombotic therapy on the recurrence of placenta-mediated diseases in pregnancy.
    Neykova K; Dimitrova V; Dimitrov R
    J Matern Fetal Neonatal Med; 2022 Apr; 35(8):1462-1468. PubMed ID: 32403962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials.
    Rodger MA; Gris JC; de Vries JIP; Martinelli I; Rey É; Schleussner E; Middeldorp S; Kaaja R; Langlois NJ; Ramsay T; Mallick R; Bates SM; Abheiden CNH; Perna A; Petroff D; de Jong P; van Hoorn ME; Bezemer PD; Mayhew AD;
    Lancet; 2016 Nov; 388(10060):2629-2641. PubMed ID: 27720497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pravastatin for severe preeclampsia with growth restriction: Placental findings and infant follow-up.
    Fruci S; Salvi S; Moresi S; Gallini F; Dell'Aquila M; Arena V; Di Stasio E; Ferrazzani S; De Carolis S; Lanzone A
    Eur J Obstet Gynecol Reprod Biol; 2023 Apr; 283():37-42. PubMed ID: 36764034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pregnancy outcomes in nulliparous women with positive first-trimester preterm preeclampsia screening test: the Great Obstetrical Syndromes cohort study.
    Boutin A; Guerby P; Gasse C; Tapp S; Bujold E
    Am J Obstet Gynecol; 2021 Feb; 224(2):204.e1-204.e7. PubMed ID: 32777265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Placenta-mediated pregnancy complications in women with a history of late fetal loss and placental infarction without thrombophilia: risk of recurrence and efficacy of pharmacological prophylactic interventions. A 10-year retrospective study.
    Borella F; Marozio L; Bertschy G; Botta G; Bertero L; Cassoni P; Maina A; Cosma S; Benedetto C
    J Matern Fetal Neonatal Med; 2023 Dec; 36(1):2183748. PubMed ID: 36860098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspirin for the Prevention of Preeclampsia and Intrauterine Growth Restriction.
    Roberge S; Odibo AO; Bujold E
    Clin Lab Med; 2016 Jun; 36(2):319-29. PubMed ID: 27235915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group.
    Branch DW; Peaceman AM; Druzin M; Silver RK; El-Sayed Y; Silver RM; Esplin MS; Spinnato J; Harger J
    Am J Obstet Gynecol; 2000 Jan; 182(1 Pt 1):122-7. PubMed ID: 10649166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of low-molecular-weight heparin on placenta-mediated fetal growth restriction in a tertiary referral hospital: A 7-year retrospective cohort study.
    Xu J; Tang Y; Peng B; Zhang WH; Wang X
    Int J Gynaecol Obstet; 2024 Apr; 165(1):220-228. PubMed ID: 37726961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-molecular-weight heparin for the prevention of preeclampsia in high-risk pregnancies without thrombophilia: a systematic review and meta-analysis.
    Chen J; Huai J; Yang H
    BMC Pregnancy Childbirth; 2024 Jan; 24(1):68. PubMed ID: 38233773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The comparison of placental abruption coupled with and without preeclampsia and/or intrauterine growth restriction in singleton pregnancies.
    Ni S; Wang X; Cheng X
    J Matern Fetal Neonatal Med; 2021 May; 34(9):1395-1400. PubMed ID: 31248311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.